RaQualia Pharma Inc. (4579)
Market Closed
10 Aug, 06:00
JPX JPX Primary ¥
515. 00
-4
-0.7707%
¥
22.11B Market Cap
- P/E Ratio
- Div Yield
134,300 Volume
- Eps
¥ 519
Previous Close Want to track 4579 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
4579 closed Monday lower at ¥515, a decrease of -0.7707% from Friday's close, completing a monthly increase of 9.3418% or ¥44. Over the past 12 months, 4579 stock lost -48.4484%.
4579 is not paying dividends to its shareholders.
The last earnings report, released on May 20, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
RaQualia Pharma Inc. (4579) FAQ
What is the stock price today?
The current price is ¥515.00.
On which exchange is it traded?
RaQualia Pharma Inc. is listed on JPX.
What is its stock symbol?
The ticker symbol is 4579.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 22.11B.
Has RaQualia Pharma Inc. ever had a stock split?
No, there has never been a stock split.
RaQualia Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | JPX Exchange | JP3967150008 ISIN |
| Japan Country | 85 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
RaQualia Pharma Inc. is a pharmaceutical company engaged in the discovery and development of new pharmaceutical compounds with a global outreach. Since its incorporation in 2008, the company has been headquartered in Nagoya, Japan. RaQualia Pharma focuses on the development of drugs for both humans and animals, covering a wide range of medical conditions such as gastroesophageal reflux disease, cancer, pain management, chronic kidney disease in cats, osteoarthritis in dogs, and several others. The company is committed to research and innovation, participating in collaborations, such as with Socium Corporation and Epigeneron, Inc., to advance its developmental pipeline and bring new therapeutic solutions to the market.
Products and Services
- Tegoprazan: A drug in phase 3 clinical trial in the United States for the treatment of gastroesophageal reflux disease.
- Grapiprant: Currently in phase I clinical trial in China and the United States for cancer treatment, and also available as a veterinary product for osteoarthritis in dogs. Additionally, grapiprant is being considered for pain management in humans.
- Ghrelin Receptor Agonist: Developed for the treatment of cancer-related anorexia/cachexia syndrome and constipation resulting from spinal cord injury.
- ELURA: A drug for managing weight loss in cats suffering from chronic kidney disease.
- TRPM8 Blocker: In development for the indication of chronic pain treatment.
- Motilin Receptor Agonist: Aimed at treating gastrointestinal dysmotility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus.
- 5-HT4 Partial Agonist: Being developed to treat gastroparesis, functional dyspepsia, and chronic constipation.
- 5-HT2B Antagonist: Targeted at treating irritable bowel syndrome with diarrhea.
- EP4 Antagonist for Dogs: A pain management drug specifically designed for canines.
- Serotonin 5-HT2A and Dopamine D2 Receptor Blocker: Focused on the treatment of schizophrenia.
- EP4 Antagonist for Cancer: Currently in phase I clinical trial as a cancer treatment.
- Cyclooxygenase-2 Inhibitor: In phase I clinical trials for pain treatment.
- CB2 Agonist for Pain: Under development for pain management.
- Selective Sodium Channel Blocker: Investigated for the treatment of pain and itch.
- P2X7 Receptor Antagonist: In Phase 2 clinical trials for the indication of chronic pain treatment.
Contact Information
Address: Meieki Southside Square
Phone: 81 52 446 6100
Website: https://www.raqualia.com
